A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.
Cancer biology & therapy. 2017 May 05 [Epub ahead of print]
Daniel Tuerff, Tristan Sissung, William D Figg
a Clinical Pharmacology Program; Medical Oncology Branch; CCR; NCI/NIH ; National Cancer Institute ; Bethesda , MD USA.